Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PBIO Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2021 Financial Results and Provide Business Update
https://www.accesswire.com/695621/pressure-biosciences-inc-to-discuss-fourth-quarter-and-fiscal-year-2021-financial-results-and-provide-business-update
Conference Call Scheduled for Tuesday, April 5 at 4:30pm ET
SOUTH EASTON, MA / ACCESSWIRE / April 1, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2021 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.
The teleconference will include a Company presentation followed by a Question & Answer period.
Date: Tuesday, April 5, 2022. Time: 4:30 PM Eastern Time (ET).
To attend this teleconference, live by telephone: Dial-in: (888) 506-0062 (North America); (973) 528-0011 (International). Verbal Access Code: 648452 (or say Pressure BioSciences Conference Call)
For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, April 6, 2022. The replay will be accessible via telephone and the Company's website for 30 days.
Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int'l); Replay Passcode: 45153.
Major major short here !!! Let’s go only 8 million in the float !
Wow this one we are backing truck up , huge deal with major bottler is on horizon.
$PBIO Pressure BioSciences Updates Stakeholders with Solid Progress on Key 2022 Goals: UST Commercial Release, Major Revenue Increase, Continued Financial Position Improvement, and Planned Uplist to National Market
https://www.accesswire.com/693489/pressure-biosciences-updates-stakeholders-with-solid-progress-on-key-2022-goals-ust-commercial-release-major-revenue-increase-continued-financial-position-improvement-and-planned-uplist-to-national-market
Company Reports Record Instrument Orders in March, Expands BaroFold Platform Services, Builds Strong Demand for Initial UST Tolling Services, and Prepares Foundation for Uplisting
SOUTH EASTON, MA / ACCESSWIRE / March 17, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today updated stakeholders on the Company's key 2022 goals. The Company believes these goals are attainable in the current fiscal year and that their achievement will put PBI on a rapid path to sustained growth, value increase, and profitability.
Mr. John B. Hollister, Director of Marketing and Sales at PBI, commented: "The 2020 pandemic year was very challenging for PBI. With a majority of our customers being academic and industrial laboratories, many were actually closed for much of 2020. Fortunately, most reopened in early 2021, which resulted in a return of strong product revenue for all of FY 2021. With continued laboratory openings in late 2021 and early 2022, and strongly renewed interest in PBI's innovative product line, we are pleased to report the receipt of more instrument orders in the month of March 2022 than in any single calendar month in our history. We believe this strong demand trend will continue throughout 2022, and beyond."
Mr. Richard T. Schumacher, President and CEO of PBI added: "In addition to the record number of instrument orders for a month, interest and engagement with our enabling BaroFold Platform protein refolding services has grown significantly over the past few months. We have also made measurable progress thus far in Q1 2022 in preparing for the commercialization of our revolutionary Ultra Shear Technology™ (UST™) Platform. Of particular note, we have significantly improved our balance sheet and solidified the foundation for our planned uplisting from the OTC Markets to a national exchange before year's end. We have an exciting year ahead: we are prepared and ready for the challenge."
A progress update on the Company's four key 2022 goals:
Achieve Significant FY 2022 Revenue Increase
Record monthly instrument sales reported for March 2022. We expect interest and upward trend to continue.
PBI Agrochem sales started slowly pending planned assets acquisition. We expect strong Q2 2022 sales.
Discussions with key pharma groups expected to lead to significant BaroFold services contracts.
Ultra Shear Technology (UST) Platform Commercialization
First commercial system ("BaroShear MAX") successfully installed at The Ohio State University (January).
Gala unveiling for major global food/beverage companies planned for May/June 2022.
East and west coast UST tolling sites ("fee for service") expected to be operational by Q4 2022.
UST contracts expected to be signed with cosmetics, nutraceutical, and agrochem customers prior to Q4 2022.
Initial build of UST systems to be complete by year-end for 2023 placements under lease/license agreements.
Strengthen Financial Position
Dramatic improvements to debt structure nearly complete.
80% of current loan debt has agreed to convert to equity upon uplist. Half of remaining loan debt expected to follow.
Uplist to NASDAQ or NYSE
A plan to meet requirements of NASDAQ/NYSE to qualify for 2022 uplisting developed and executing smoothly.
Mr. Jeffrey N. Peterson, PBI's Board Chairman, provided a broader context: "Our team has performed admirably in challenging circumstances, to build strong growth in interest, trials, and results around each of our technology platforms. We are especially pleased with our excellent progress in resolving debt and accrued expense balances and consequent strengthening of our balance sheet in preparation for our UST services and licensing launch, our planned agrochemical company assets acquisition, and a new trajectory of accretive growth, all in preparation for the completion of our long-planned NASDAQ or NYSE uplisting. We thank our loyal investors for their strong multi-year support, as we zero in on our expected transition to profitability in 2023."
$PBIO Emerging Technology Insider Releases a New TechTalks Video Interview Featuring Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc.
https://www.accesswire.com/692494/emerging-technology-insider-releases-a-new-techtalks-video-interview-featuring-richard-t-schumacherceo-and-founder-of-pressure-biosciences-inc
Discussions Centered on the Expanding Partnership Between Pressure BioSciences & The Ohio State University, the Food Industry Consortium, and the Exciting Market Potential for the Ultra Shear Technology Platform
DENVER, CO / ACCESSWIRE / March 10, 2022 / Emerging Technology Insider today announced a new TechTalks video featuring an interview with Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc. (OTCQB:PBIO).
Pressure BioSciences is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to multiple worldwide industries, such as food and beverage, biotherapeutics, nutraceuticals, cosmetics, and personal wellness.
The TechTalks video is viewable at www.EmergingTechnologyInsider.com. It can also be accessed through the following link: TechTalks Video.
In the TechTalks video, Mr. Schumacher provides his insight into the recent Ohio State press release regarding Pressure BioSciences' soon to be commercially released Ultra Shear Technology™ (UST™). This innovative, patented processing system, called the BaroShear UST MAX, was recently installed and commissioned in the Advanced Food Processing Technology Pilot Plant of the College of Food, Agricultural, and Environmental Sciences at Ohio State.
In the TechTalks video, Mr. Schumacher discussed in detail many of the accomplishments expected to result from the previously announced formation of the Food Industry Consortium, co-led by Pressure BioSciences and Ohio State.
The press release indicated that the Consortium's mission was to help companies manufacture higher quality, longer shelf-life, and safer liquid foods and beverages. The Consortium is open to food companies worldwide.
The Ohio State press release also indicated that utilizing Pressure BioSciences' proprietary UST platform, liquid food and beverage producers will be able to reduce and perhaps even eliminate the need for chemical additives and damaging heat that is utilized in current processing methods, thus enabling the production of healthier, more nutritious products with greater appeal to modern consumers.
The press release also announced that Pressure BioSciences and Ohio State intend to initiate an aggressive outreach program in the Spring 2022 and expect to welcome a global group of preeminent food and beverage companies as Consortium members.
Consortium members will help direct Ohio State's and Pressure BioSciences' efforts across a universe of liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability.
In the press release, Ohio State stated that the applications of Pressure BioSciences' Ultra Shear Technology extend into nutraceutical products, including infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers.
The Ohio State press release is viewable here.
$PBIO Pressure BioSciences, Inc. Discusses the Significant 2022 Revenue Potential of Its Innovative and Enabling Ultra Shear Technology Platform with The Stock Day Podcast
https://www.newsfilecorp.com/release/112674/Pressure-BioSciences-Inc.-Discusses-the-Significant-2022-Revenue-Potential-of-Its-Innovative-and-Enabling-Ultra-Shear-Technology-Platform-with-The-Stock-Day-Podcast
Phoenix, Arizona--(Newsfile Corp. - February 3, 2022) - The Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or "the Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based products and services for the worldwide life sciences, food and beverage, nutraceuticals, and other industries. President and CEO of the Company, Mr. Richard T. Schumacher, joined Stock Day host, Everett Jolly.
Mr. Jolly began the interview by asking: "Could you provide a quick overview of your three patented pressure-based technology platforms?"
Mr. Schumacher responded: "We have developed the ability to capture and safely use many of the marvelous properties and benefits of pressure in the medical and scientific field. We have designed and developed instruments that can generate pressure from 500 to 100,000 PSI. Scientists, manufacturing personnel, food technologists, and others use the pressure generated by our instruments to increase the quality of their research studies, to decrease the cost of manufacturing their products, and to improve important analytical testing methods, just to name a few of the applications of pressure. It is important to note that the controlled pressure we use, even at high pressure, is extremely safe because we are using hydrostatic (water) pressure. Water barely compresses, even under intense pressures, so in the very rare case where something did go wrong, the compressed water will not explode, but simply get released through a safety port."
Mr. Schumacher then elaborated on the numerous applications for the PBI pressure-based technologies they have developed, giving examples such as the release of DNA, RNA, lipids, or proteins from tissue biopsy samples, killing pathogens in food and beverages, as well as cracking open cells, viruses, and bacteria for more in-depth studies of infectious diseases, cancer, Alzheimer's disease, and other diseases and disabilities.
Mr. Schumacher continued: "We have three exciting and very enabling technology platforms. The first platform is called Pressure Cycling Technology, or PCT. We currently have fifteen issued PCT patents; four different instrument designs; over 200 customers globally; over 250 published scientific papers by independent research groups; and about 350 instruments installed worldwide. PCT is primarily being used in preparing samples for scientific research and in the quality control of biopharmaceuticals. The second technology platform is called the BaroFold Technology. Baro stands for pressure, fold for folding. Biopharmaceutical companies actually make the proteins used in today's protein-based drugs (e.g., monoclonal antibodies, vaccines, biotherapeutics) in huge vats in production facilities. In this type of process, there are a number of things that can go wrong. Two of the most common problems are that the protein molecule being made actually misfolds (it is not the exact structure that it has to be in order to work and thus be released as a safe efficacious drug), or the proteins being made aggregate (clump) with other proteins in the vat. Aggregated proteins can't be used as drugs - so unless the aggregation is fixed, the material being made (which could be worth millions of dollars) would have to be discarded. Pressure has the innate ability, in some cases, to fix one or both of those huge problems. If fixed, the protein can then be used to make the vaccine, therapeutic drug, etc. We have eight issued patents in this field that allow us to work with companies that are developing protein-based drugs, and that keep others from competing against us in this very exciting and potentially highly profitable biopharma business."
Mr. Schumacher then discussed the Company's third platform, Ultra Shear Technology, or UST, "Last August when you and I last spoke Everett, PBI had a couple of issued patents related to UST. Today we have 7 issued patents, plus a ton of proprietary knowledge in the UST area. This is a very exciting technology platform, perhaps our most exciting, because it can be used across the board in so many different fields, and for so many different applications. What the UST platform essentially does is that it allows oil and water to mix, to actually combine with each other and not separate out, and to stay combined for very, very long periods of time. Imagine the potential. Everywhere oil is used in a product, we can make that oil more water soluble, more stable. The universe of potential fields includes food and beverage, nutraceuticals and other wellness products, biopharmaceuticals, cosmetics, agrochemicals, and even industrial oils and lubricants."
Mr. Jolly then commented on what he said was the enormous revenue potential of PBI's three pressure-based technology platforms, as well as on an announcement detailing a key milestone that was reached in the Company's Ultra Shear Technology commercialization efforts, and asked: "Could you expand on this announcement?"
Mr. Schumacher then elaborated on the many potential applications of their UST platform; he especially highlighted the benefits that the UST platform could bring to the development of better quality, more stable, and more water-soluble CBD products with greatly enhanced bioavailability. Mr. Schumacher explained: "Human and other animal bodies are water-based, as are many of the plants on earth. It is very difficult for water-based animals and plants to absorb an active ingredient that is ingested or applied that is contained in an oil drop. A good example is CBD, which comes out of the cannabis plant in an oil. When a CBD-containing food, beverage, therapeutic, cosmetic, or nutraceutical is ingested or applied to water-based humans or other animals (e.g., pets), it is hard for the water-based body of the human or other animal to absorb the active ingredient out of the oil before the oil is excreted from the body. Consequently, most of the CBD is usually lost. It has been estimated that perhaps only 5-20% of CBD in CBD-containing products is actually absorbed. UST processes the CBD oil drops into tiny, nano-sized, highly water soluble, CBD-containing oil droplets, which are easy for water-based animals to absorb. Thus, the bioavailability of the CBD product should significantly increase, making far more of the CBD available to the body to offer its beneficial qualities."
Mr. Schumacher then discussed the Company's success in nanoemulsifying other active ingredients currently being sold as nutraceutical/wellness products, including Astaxanthin, one of the most potent antioxidants on the face of the earth. It is estimated that Astaxanthin is 6,000 times more potent than Vitamin C. He then elaborated on other markets, including applications in the biopharmaceutical, cosmetics, and agrochemical industries.
The conversation then turned to the potential use of Ultra Shear Technology in the food and beverage industry, a $5.5 trillion market. The food and beverage industry includes hundreds if not thousands of popular emulsions, including milk, ice cream, salad dressings, vitamin water, juices, and many, many more products.
Mr. Jolly then asked: "Could you give your shareholders and my listeners a timeline about what is going to happen this year?"
Mr. Schumacher shared: "We announced yesterday that we recently shipped our first industrial-scale commercial UST instrument (the BaroShear MAX) to the Ohio State University's College of Food, Agriculture and Environmental Sciences, one of the top food and beverage colleges in the world. It has now been installed in their highly regarded Food Pilot Plant. Five scientists have been trained and commissioned to work on the UST instrument. Their plan over the coming weeks is to test the MAX to the max - they will be running a number of tests to ensure that the instrument does what it is expected to do. Once this has been confirmed, we and Ohio State (acting as a Safe Food Consortium) will invite food and beverage companies from around the world to visit the university, watch demos of the BaroShear MAX, join the Consortium, and help Ohio State and PBI design and carry out studies to determine if the UST platform can help improve the quality, taste, color, flavor, nutritiousness, and stability of some of their food and beverage products. If so, they will have a first right to license the technology."
Mr. Schumacher continued: "It is great to have an academic institution as your partner, but to have Ohio State and their College of Food, Agriculture, and Environmental Sciences, as well as Dr. Bala, a world-renowned food scientist and a pioneer in using pressure to make food safer, is an unbelievable privilege."
As the interview came to a close, Mr. Jolly asked: "What do you want my listeners and your shareholders to take away from today's interview?"
Mr. Schumacher responded: "I want to thank all PBIO shareholders for their support over the years. It has been a long time coming, but we believe we are on to something very special, very enabling, and potentially very big…and that is based on the upcoming commercial release of the UST Platform. So again, I want to thank everyone for their patience as a shareholder or stakeholder. We believe that with our 30 issued patents, our three technology platforms (all be commercial by year's end), the incredible staff at PBI - most of whom have been at PBI for 10 years or longer, and with a number of very large and growing markets that all have issues that our technology platforms can fix, that we believe we are extremely undervalued at the moment. We understand that much of value is placed on revenue, so it is important to tell your listeners that I firmly believe that with the commercial release of UST during the second half of the year, supported by anticipated growth in both the BaroFold and PCT platforms, 2022 is the year where real revenue is going to start. And we also believe that profitability is just around the corner."
$PBIO Pressure BioSciences Ultra Shear Technology Commercialization Achieves Key Milestone: Production-Scale System Commissioned at Ohio State to Serve Food Industry
https://www.accesswire.com/685789/pressure-biosciences-ultra-shear-technology-commercialization-achieves-key-milestone-production-scale-system-commissioned-at-ohio-state-to-serve-food-industry
Installation of BaroShear MAX UST System in Acclaimed The Ohio State University Food Pilot Plant Will Introduce Global Food Industry to Preparation of Safer, More Nutritious Liquid Foods and Beverages
SOUTH EASTON, MA / ACCESSWIRE / January 27, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and process development services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced the commissioning of its first production-scale, patented Ultra Shear Technology™ ("UST™") platform. The BaroShear MAX UST processing system was installed and commissioned in The Ohio State University College of Food, Agricultural, and Environmental Sciences ("CFAES"). Along with the previously announced formation of the Food Industry Consortium, co-led by PBI and Ohio State, this completes one of the last remaining critical milestones in the UST platform deployment at Ohio State to serve the global food industry.
The Consortium's mission is to help companies manufacture higher quality, longer shelf-life, and safer liquid foods and beverages. Utilizing PBI's proprietary UST platform, producers can reduce/remove chemical additives and damaging heat in current processing methods, enabling the production of healthier, more nutritious products with greater appeal to modern consumers. The Consortium is open to food companies worldwide. Ohio State and PBI plan to initiate an aggressive outreach program in the Spring 2022 and expect to welcome a global group of preeminent food & beverage companies as Consortium members shortly thereafter. Members will help direct Ohio State and PBI efforts across a universe of prospective liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability. UST applications development will also extend into nutraceutical products, such as infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers. Consortium members will have a first-right to license new applications and methods.
Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a key innovator in the development of high pressure-based food technologies, commented: "Over the past 20 years, high pressure processing ("HPP") has emerged as a highly successful, clean-label approach for food quality and safety. The HPP market was estimated at $15.5 billion in 2019. HPP is a versatile technology, but it does not employ critical fluid shear forces like UST, which are essential when particle or droplet size reduction is required for better stability, texture, taste, and bioavailability. Our UST platform uniquely combines the benefits of high hydrostatic pressure, extreme fluid shear, and controlled temperature to achieve these results. Food proteins and lipids, processed by UST, result in true nanoemulsions with improved appearance, taste, smell, texture, nutrition, stability, and bioavailability - all of which are important attributes to liquid foods, such as sauces, beverages, and even ice cream. Importantly, UST not only can produce the highest quality nanoemulsions, but this innovative process can also help destroy bacteria and other pathogens, and reduce/eliminate the need for chemical additives, thus increasing food safety."
Dr. Alexander V. Lazarev, Chief Science Officer of PBI, added: "We believe the ability to modify physical attributes and safety/stability through the physics of shearing and pressure, rather than chemical additives and heat, will create a multitude of new opportunities in the development of new or improved products in other areas, such as cosmetics, nutraceuticals, and pharmaceuticals. Additionally, nanoemulsions are already beginning to play a major role in advanced therapeutics."
Mr. Richard T. Schumacher, President and CEO of PBI, explained: "We expect to begin placing commercial processing units into the market during the third/fourth quarters of 2022, under a leasing and licensing model. As new and commercially-relevant UST applications are demonstrated, and Consortium members utilize their first rights to license them for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales. In addition, PBI will drive the commercialization of these new applications amongst non-Consortium food companies worldwide and through multiple other major industries beyond food and beverages."
Sponsorship of UST development by the U.S. Department of Agriculture's NIFA program is deeply appreciated.
$PBIO Innovations & Advancements in the CBD Market. 012021
https://vimeo.com/669442206
$PBIO Pressure BioSciences to Participate in FORCE Family Office's January 20th Webinar: Innovations and Advancements in the $4.6 Billion CBD Market
https://www.accesswire.com/684551/Pressure-BioSciences-to-Participate-in-FORCE-Family-Offices-January-20th-Webinar-Innovations-and-Advancements-in-the-46-Billion-CBD-Market
Did PBIO complete the Aquistion or Merger of Cannaworx Holding?
$PBIO Pressure BioSciences Shatters Preconceived Nanoemulsion Stability, Performance, and Production Limits: Produces CBD Oil Nanoemulsions with 18 Month Stability
https://www.accesswire.com/679117/pressure-biosciences-shatters-preconceived-nanoemulsion-stability-performance-and-production-limits-produces-cbd-oil-nanoemulsions-with-18-month-stability
UST Platform's Ultra-low Droplet Sizes and Test Verified Stability Portends Revolution in Major Markets
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food & beverage industries, today announced that hemp-derived cannabidiol ("CBD") processed with its patented Ultra Shear Technology™ ("UST™") platform produced high-quality water-soluble nanoemulsions of CBD oil in water that have now demonstrated rock-solid visual and analytical stability 18 months after production and baseline testing.
CBD is a widely popular therapeutic for relief of anxiety, depression, and PTSD, as well as chronic inflammatory and neuropathic pain. It is FDA-approved for use in the control of epileptic seizures in Lennox-Gastaut syndrome and Dravet syndrome. Early research suggests that CBD reduces spasticity in multiple sclerosis and may lessen the severity of neurological symptoms associated with Alzheimer's Disease, Parkinson's disease, and schizophrenia. CBD is under investigation as a palliative adjunctive therapy in cancer.
However, CBD is insoluble in water and is poorly absorbed by the human body. The World Health Organization (WHO) estimates that as little as 6% of CBD is absorbed via current oral delivery routes. Thus, most ingested CBD is wasted, passing through the body without being absorbed. Consequently, there is enormous interest in the development of truly water-soluble CBD to deliver efficient dosing, absorption, bioavailability, and benefit from CBD products (e.g., foods and beverages, therapeutics).
Dr. Alexander V. Lazarev, Chief Science Officer of PBI, explained: "Nanoemulsions, liposomes, and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles the better the stability and bioavailability of these preparations. Once the droplets/particles reach below about 100 nanometers, nanoemulsions appear optically clear and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability, and importantly, their shelf life. Moreover, these preparations can be filter-sterilized to comply with FDA requirements for injectable drugs. Today we are pleased to announce that our enabling, affordable, and scalable UST process has been shown to create nanoemulsions that maintain rock-solid stability, excellent water solubility, and pristine visual clarity at room temperature for at least 18 months. These results offer the potential to significantly increase shelf-life and effectiveness for CBD and a multitude of other oil-based products in use today."
Mr. Gary B. Smejkal, Senior Research Scientist at PBI, explained the Company's breakthrough: "The intense fluid shearing in UST progressively decreases oil droplet size with each cycle, making the method highly tunable while enabling the user to select and reliably reach a target droplet size. We have demonstrated that our platform consistently produces CBD nanoemulsions of uniform 30-40 nm droplet sizes that are stable at room temperature for at least 18 months. Measurements of droplet size by Dynamic Light Scattering (DLS) over time courses at various temperatures have shown that particle size remains unchanged over prolonged storage at room temperature or refrigeration, a major indication of nanoemulsion stability. Clarity, quantified by UV/Vis spectroscopy, also remains unchanged for equally long periods of time, making the CBD nanoemulsion visually undetectable when infused into bottled water or other beverages."
$PBIO Pressure BioSciences Awarded Second U.S. Patent for Its Revolutionary Ultra Shear Technology Platform, for Its Innovative NanoGap Valve
https://www.accesswire.com/672314/pressure-biosciences-awarded-second-us-patent-for-its-revolutionary-ultra-shear-technology-platform-for-its-innovative-nanogap-valve
Dynamically-Adaptive Compact Valve is Key Component in the Company's Highly Anticipated and Proprietary UST Platform; UST Expected to Help Deliver Strong Sales Growth and Profitability in 2022
SOUTH EASTON, MA / ACCESSWIRE / November 11, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialized services to the worldwide life sciences, agriculture, cosmetics, food & beverage, and other industries, today announced the award of its second U.S. patent for its revolutionary Ultra Shear Technology™ (UST™) platform. Entitled "Ultrahigh Pressure Compact Valve with Throttling Capability", this new patent (US 11,156,295) brings the Company's intellectual property ("IP") estate to a total of seven UST patents (two in the U.S.) and 30 pressure-based patents worldwide.
The Company's UST platform was created to revolutionize the processing of immiscible liquids (typically oils and water) - usually processed into macro/micro emulsions - into high quality, highly valuable, long-term stable nanoemulsions. Emulsions are mixtures of two or more liquids that are normally not soluble in each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in thousands of products in everyday use, such as in dairy products, lotions and creams, drugs and vaccines, and nutraceuticals. Scientific data indicate that higher bioavailability and improved absorption in humans, animals and plants, plus greater stability, lower surfactant levels, and other advantages (such as more reliable dosing control) are vastly improved by high quality nanoemulsions versus micro or macroemulsions.
Dr. Edmund Y. Ting, Sr. Vice President of Engineering and an inventor on this patent, said: "The conversion of a coarser emulsion into a high-quality nanoemulsion with ultra-low droplet size is made possible by intense fluid shear forces created from pressure driven fluid velocity. By using pressures up to 60,000 psi to drive fluid flow, we believe that UST achieves a disruptive shear capability greater than any homogenizer on the market today. UST also achieves higher flow rates and lower processing costs than current high-pressure homogenizers by leveraging the use of field proven pumps, patented pressure transfer isolators, and our now patented, self-throttling Nanogap™ valve. The unique design of this compact, self-throttling valve is dynamically-adaptive, delivering clog and erosion resistance, with extraordinary precision and control in producing fine nanoemulsion dispersion size."
Dr. Alexander V. Lazarev, Chief Science Officer, commented: "We are proud to see our work recognized with yet another strong patent. Amongst the exciting applications of our UST platform are enormous opportunities in the efficient and affordable production of stable nanoemulsions. Nanoemulsions are promising revolutionary advances in food/beverage, nutraceutical, personal care, pharmaceutical, agriculture, as well as many other industries. The UST process features exquisite control of high shear energy, resulting in a very reproducible product with a narrow distribution of droplet sizes as small as 40 to 100 nanometers. Such tiny, nano-sized oil droplets lead to greater stability and higher bioavailability of the active ingredients contained in the oil phase, resulting in more nutritional and better tasting liquid foods and beverages, as well as significantly higher quality drugs and vaccines in dosing and delivery."
Mr. John B. Hollister , Director of Marketing and Sales, stated, "The daily market interest we are receiving in UST-produced nanoemulsions prior to significant active promotion activities is very exciting. The potential benefits of nanoemulsified products are now recognized by important market leaders globally. The 2021 worldwide market size for a number of industries that could benefit from UST are each in the tens and even hundreds of billions of dollars. Over the past year, we have been working with major players in several of these markets to create unique formulations, the results of which have been embraced by these prospective partners. These companies are exerting tremendous pressure on us to release the commercial-scale, UST systems as quickly as possible. We believe the amount of nanoemulsified product required to meet these customers' needs will clearly help us achieve our goals of strong sales growth and profitability in 2022."
For more information on PBI's innovative UST, BaroFold, and PCT Platforms, and on the Company's new PBI Agrochem Division, please use the link to follow Mr. Schumacher's interview on Benzinga's ALL ACCESS Investor Event on Thursday, November 4, 2021. Schumacher Interview ALL ACCESS 11.4.21
$PBIO Pressure BioSciences’ BaroFold Platform Unleashes Hidden Growth Engine as Strong Demand for Protein Therapeutics Leverages PBI’s Protein Refolding Technology
https://www.accesswire.com/671146/pressure-biosciences-barofold-platform-unleashes-hidden-growth-engine-as-strong-demand-for-protein-therapeutics-leverages-pbis-protein-refolding-technology
Titans and Emerging Leaders of Biopharma Struggling with Protein Misfolding and Aggregation Issues that Threaten Enormous Revenue Potentials Are Turning to PBI's Uniquely Enabling BaroFold Solution
REMINDER: PBI to Participate in the Benzinga Virtual ALL ACCESS Investor Event Today at 11:20 am ET.
SOUTH EASTON, MA / ACCESSWIRE / November 4, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments, platform technologies, and related consumables for the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the strategic expansion of its patented BaroFold technology platform, with continued growth in services, sales and leasing.
Because of their high degree of specificity, proven efficacy, and minimal side effects, proteins have become the biological molecule of choice in therapeutic drug development. The global protein therapeutics market is expected to reach US $233 billion by 2027. Unfortunately, the manufacture of proteins as biological therapeutics is time-consuming, complex, and struggles with persistent challenges.
Dr. Alexander V. Lazarev, PBI's Chief Science Officer, said: "The biosimilars market for generic biotherapeutics is rapidly expanding worldwide and it demands lower costs of biotherapeutics. Biomanufacturing throughput and production costs can be slashed significantly if protein drugs are expressed in bacterial cells. Traditionally, bacterial systems were considered inferior to the cell cultures obtained from higher organisms due to higher incidence of certain issues, such as the formation of aggregates and the "misfolding" of polypeptides that fold in a specific pattern to give a protein its function. PBI's BaroFold™ technology platform, based on the innovative use of high pressure and protected by the Company's eight issued patent families, offers a uniquely gentle, exquisitely controllable, and cost-effective way to address these manufacturing challenges. To capitalize on this opportunity, PBI launched the BaroFold Biopharma Services Business ("BaroFold Services") in 2019."
Dr. Vera Gross, Director of Applications Development, commented: "The BaroFold platform can be applied to the development, production, and post-storage remediation of many different therapeutic proteins. The technology is scalable and practical for standard bioprocess environments. To put it simply, the BaroFold process uses physics where traditional processes use chemistry with arduous procedures and difficult cleanups. This means that the use of aggressive and toxic chemicals in the protein manufacturing process can be replaced in whole, or in part, by the use of high hydrostatic pressure. Thus, with this unique technology platform, we help our biopharma clients create and manufacture high quality novel protein therapeutics and biosimilars, while also lowering the cost of production and the environmental costs of chemical use and disposal. The benefits of the BaroFold platform are manifest in feedback from our customers and in their repeat business."
PBI's BaroFold Services business has grown significantly over the past two-plus years, from one customer in 2019, to two customers in 2020, to four in 2021. Current customers run the gamut from well-funded startups to multi-billion-dollar global biopharmaceutical companies. Such companies contract PBI to develop bioprocess steps utilizing the BaroFold Platform that can increase quality, reduce manufacturing costs, improve processing yields, and reduce the time to market for their planned protein-based therapeutics, each with sales potential from millions to a billion dollars, or more.
Mr. John B. Hollister, Director of Sales and Marketing, added: "The benefits of the BaroFold platform allow us to work with biopharma customers from the early stages of a protein drug's development. Initial contracts with the customer's R&D team will focus on showing Proof of Concept (POC). Once POC is demonstrated, we will continue to contract BaroFold Services as drug candidates move through successive stages of analysis and development: from pilot-scale processing, through volume scale-up, and finally to commercialization. Ultimately, the BaroFold platform will become Standard Operating Procedure for production of the protein therapeutic. From the biopharma's perspective, benefits include the commercialization of a drug that might otherwise never make it to market, as well as a potential increase in quality and decrease in manufacturing costs. From PBI's perspective, benefits include additional rounds of service fees, equipment sales/leases, and finally BaroFold license fees. For a commercially successful protein therapeutic, the licensing stream is expected to be extremely lucrative."
Mr. Hollister continued: "Recently it became evident that some biopharma companies developing protein-based therapeutics had libraries of protein drug candidates they would like PBI to evaluate, but it would be too costly to test them all through the BaroFold Service. Our due diligence indicated that if they had use of our small-scale BaroFold platform equipment, they could screen their library themselves and send to PBI only those that evidenced the most potential. We quickly set up a sale/leasing program to fulfill these needs. Recently, we leased two small-scale systems to a multi-billion-dollar biotech company and are in discussions with additional interested groups. Having now proven the concept, we believe this program will add greatly to the number of protein candidates utilizing our BaroFold services going forward, and that we will consequently see an increase in instrument/consumable revenue from biopharma companies in the protein therapeutic development space."
$PBIO Wallstreet Researcher Pressure Biosciences Research Report -
http://www.wallstreetresearcher.com/Images/PBIO.pdf
$PBIO Pressure BioSciences to Participate in the Benzinga ALL ACCESS Investor Event
https://www.accesswire.com/670731/pressure-biosciences-to-participate-in-the-benzinga-all-access-investor-event
Company Invites Individual and Institutional Investors, as well as Analysts and Advisors, to Attend Its Live, Virtual Guest Appearance on Thursday, November 4, 2021
SOUTH EASTON, MA / ACCESSWIRE / November 2, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the Company's participation in Benzinga's November 4th ALL ACCESS Investor Event. This real-time, virtual event will feature up to 12 companies in a unique, first-of-a kind format that effectively comingles part interview, part investor presentation. PBI's President and CEO, Mr. Richard T. Schumacher, has been invited to participate on the show:
DATE: Thursday, November 4, 2021
TIME: 11:20 am ET
PRESENTATION: Live, Virtual
LINK TO VIEW: Click Here
Recent Company Highlights
Reported resurgent growth with our strongest financial half in three years.
Offered guidance that we expect even stronger financial results for Q3/Q4 2021.
Expect to acquire assets of global eco-friendly agrochem supplier with major Q3/Q4 2021 revenue impact.
Our patented UST™ platform processed Neem Oil into a highly potent, stable, and safe insecticide.
Announced the formation of a food industry Consortium with our partner Ohio State University.
Reported plans to set-up Toll Manufacturing Partnerships on the east and west coasts of the U.S.
Awarded four additional patents for our novel, proprietary UST platform.
Reported that UST-processed CBD oil nanoemulsions exceeded an unprecedented 12 months of stability.
Reported the UST Platform successfully processed Astaxanthin - the world's most powerful antioxidant.
Replay $PBIO Emerging Growth Conference.
Link to the video is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166165192
Next Conference October 13
Register Here:
https://goto.webcasts.com/starthere.jsp?ei=1487781&tp_key=e2bca7d62c&sti=twitter
Who do you want to see present?
Tell us here:
www.EmergingGrowth.com/Conference
EGC 17 Replay:
$CANB
$PBIO
$GNTW
$AWX / $AWG
$PETV
$UCASU
$CLSH
$MARK
$CYDY
$PBIO Pressure BioSciences UST Platform Successfully Transforms Neem Oil into a Novel, Highly Potent Nanoemulsion for More Effective Agrochemical Applications https://www.accesswire.com/666246/Pressure-BioSciences-UST-Platform-Successfully-Transforms-Neem-Oil-into-a-Novel-Highly-Potent-Nanoemulsion-for-More-Effective-Agrochemical-Applications
$PBIO Announces Forward Integration Plans for Ultra Shear Technology Demonstration and Toll Manufacturing Partnerships on U.S. West and East Coasts https://www.accesswire.com/666049/Pressure-BioSciences-Announces-Forward-Integration-Plans-for-Ultra-Shear-Technology-Demonstration-and-Toll-Manufacturing-Partnerships-on-US-West-and-East-Coasts
$PBIO Live on the Emerging Growth Conference in 30 minutes!
The Link to Register to Interact Live with the CEO's is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334
Companies Presenting:
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV
$UCASU
$CLSH
$MARK
$CYDY
Presenting now or Previously:
$CANB
$PBIO Emerging Growth Conference 17 Starts in 1 hour!
The Link to Register to Interact Live with the CEO's is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334
Companies Presenting:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV
$UCASU
$CLSH
$MARK
$CYDY
$PBIO Pressure BioSciences to Update Investors on Recent Accomplishments, Year-End Goals, Plans for Accelerating Revenue Growth, and Path to Profitability in 2022
https://www.accesswire.com/665846/pressure-biosciences-to-update-investors-on-recent-accomplishments-year-end-goals-plans-for-accelerating-revenue-growth-and-path-to-profitability-in-2022
Company to Present this Week at the Benzinga Healthcare and Emerging Growth Small Cap Conferences
SOUTH EASTON, MA / ACCESSWIRE / September 28, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced that the Company has accepted invitations to present at this week's Benzinga Healthcare and Emerging Growth Small Cap Conferences. These real-time, interactive investor conferences will feature presentations from multiple up-and-coming, innovative, and exciting small cap companies.
PBI's President and CEO, Mr. Richard T. Schumacher, will present a corporate overview - including a discussion of its resurgent revenue growth in 2021, the potential impact of the anticipated commercial release of its revolutionary Ultra Shear Technology™ (UST™) platform, its impending acquisition of assets of a global eco-friendly agrochemicals company, and its planned up-list to a U.S. national stock exchange. Mr. Schumacher's presentation information is below:
Emerging Growth Conference
DATE: Wednesday, September 29, 2021
TIME: 10:30 am EDT
PRESENTATION: Video Webcast
REGISTER (free): To Register for the Emerging Growth Conference, Click Here
Benzinga Healthcare Small Cap Conference
DATE: Thursday, September 30, 2021
TIME: 10:30 am EDT
PRESENTATION: Video Webcast
REGISTER (free): To Register for the Benzinga Healthcare Small Cap Conference, Click Here
$PBIO Pressure Biosciences CEO Live on the Emerging Growth Conference on September 29, 2021
Registration link here to interact Live:
https://goto.webcasts.com/starthere.jsp?ei=1487780&tp_key=8c67ce781e&sti=ihub
Get Your Crypto on the Conference
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
$PBIO Replay Emerging Growth Conference 14
Get the link
and...
Register for the next Conference on 9/1 here...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165547337
Who do you want to see present?
EGC 14 Presenters for Replay:
$NSAV - VirtuaBroker
$RYAH $RYAHF
$PETV
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD
$PBIO 8k & Investor Presentation
SEC Form 8k Link: https://www.sec.gov/ix?doc=/Archives/edgar/data/830656/000149315221020773/form8-k.htm
Investor Presenation Link: https://www.sec.gov/Archives/edgar/data/830656/000149315221020773/ex99-1.htm
Item 7.01 Regulation FD Disclosure.
Effective August 18, 2021, executives of Pressure BioSciences, Inc. (the “Company”) have begun using the materials included in Exhibit 99.1 to this report (the “Investor Presentation”) in connection with presentations to existing stockholders of the Company, potential investors of the Company, and the investment community. The Investor Presentation provides an overview of the Company’s strategy, performance and future objectives.
The information provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission or incorporated by reference in any filing under the Securities Exchange Act or 1934 or the Securities Act of 1933.
$PBIO Pressure BioSciences, Inc. Reports Strong Second Quarter 2021 Financial Results https://www.accesswire.com/660464/pressure-biosciences-inc-reports-strong-second-quarter-2021-financial-results
$PBIO Live on the Emerging Growth Conference in 30 minutes!
Link to watch the Conference here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165497793
Other Companies Presenting:
$TOMDF
$GRYN
$INND
$SNMN
$WNBD
Presented Earlier:
$NSAV
$RYAH $RYAHF
$PETV
$ACXP
$PBIO Pressure BioSciences to Host Q2 2021 Financial Results and Business Update on Thursday, August 19, 2021
https://www.accesswire.com/660282/pressure-biosciences-to-host-q2-2021-financial-results-and-business-update-on-thursday-august-19-2021
Company to Discuss Strong Q2 2021 Financial Results, Give Update on Current Activities, and Take Questions on Aggressive Growth Plan Laid Out for the Company on August 5, 2021
SOUTH EASTON, MA / ACCESSWIRE / August 18, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2021 financial results and provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a Company website link).
The teleconference will include a Company presentation followed by a Question & Answer period.
Date: Thursday, August 19, 2021. Time: 4:30 PM Eastern Time (ET).
To attend this teleconference, live by telephone: Dial-in (844)-602-0380 (North America); 862-298-0970 (International). Verbal Passcode: PBI Q2 2021 Financial Call and Business Update.
For those unable to participate in the live teleconference, a replay will be available beginning Friday, August 20, 2021. The replay will be accessible via telephone and the Company's website for 30 days. Replay Number: (877)-481-4010 (North America); (919) 882-2331 (Int'l); Replay Passcode: 42576.
$PBIO Pressure BioSciences to Expand on Recent Announcement of Over $1,000,000 in Orders Received by its New Eco-Friendly Agrochem Subsidiary in First Month of Operations
https://www.accesswire.com/660115/pressure-biosciences-to-expand-on-recent-announcement-of-over-1000000-in-orders-received-by-its-new-eco-friendly-agrochem-subsidiary-in-first-month-of-operations
Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive
PBI Agrochem Update, Followed by a Q&A Session, on Wednesday, August 18, 2021
SOUTH EASTON, MA / ACCESSWIRE / August 17, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the Company's participation in the August 18th Emerging Growth Conference. This real-time, interactive investor conference will feature 10 companies, presenting for 15-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking at 11:45 am and will briefly expand on the Company's recent announcement that its new eco-friendly, agrochemical subsidiary (PBI Agrochem, Inc.) has received over $1,000,000 in purchase orders in its first month of operations. The presentation will be followed by a brief Q&A session. Presentation information is below:
DATE: Wednesday, August 18, 2021 (11:45 am EDT)
PRESENTATION: Video Webcast
REGISTER: Click Here to Register for the Conference
Highlights of Recent Press Release on Receipt of Over $1,000,000 in Orders by New Eco-Friendly Agrochem Subsidiary in its First Month of Operations:
PBI announced the formation of PBI Agrochem, Inc. (new wholly owned agrochemical subsidiary) in July 2021
During the past month, PBI has been setting up a U.S. warehousing, processing, and product packaging facility
In July 2021, Company announced the purchase of over $500K of specialized proprietary bulk material
PBI has received orders for over $1,000,000 of eco-friendly agrochem pest control and growth stimulant products
Company expects the majority of the $1,000,000 in orders to ship in Q3 2021
The new Agrochem revenue will be additive to existing PBI core product revenue
PBI expects it will receive orders for additional 2021 product shipments over the coming weeks and months
Company believes revenue from new agrochem products will be significant and accretive, beginning in Q3 2021
PBI believes the combination of its Core and new Agrochem product lines will take it to profitability in 2022
$PBIO CEO Presenting on the Emerging Growth Conference on August 18. Register Now https://goto.webcasts.com/starthere.jsp?ei=1486517&tp_key=3bd9735fe4&sti=globe
$PBIO Live on the Emerging Growth Conference this Wednesday August 18, 2021.
The registration link so you can watch the live presentation is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165458105
$PBIO Pressure Biosciences CEO Live on the Emerging Growth Conference on August 18, 2021
Registration link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165417330
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
$PBIO Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations.
https://www.accesswire.com/659452/pressure-biosciences-new-eco-friendly-agrochem-subsidiary-receives-over-1000000-in-orders-in-first-month-of-operations
You understand, don't you, that that was a paid promotion:
"The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content that follows is for informational purposes only and not intended to be investing advice."
Notice how familiar it is with all the pumping PRs of the last couple weeks?
$PBIO Patents, Partnerships, and Acquisitions Propel Pressure BioSciences Toward NASDAQ or NYSE Uplisting in 2021 https://www.benzinga.com/markets/cannabis/21/08/22450041/patents-partnerships-and-acquisitions-propel-pressure-biosciences-toward-nasdaq-or-nyse-uplistin
$PBIO Pressure BioSciences Unveils Aggressive Growth Plan and Goals for Second Half 2021; Company Marches Toward UST Commercial Release, Up-listing, and Profitability https://www.accesswire.com/658506/Pressure-BioSciences-Unveils-Aggressive-Growth-Plan-and-Goals-for-Second-Half-2021-Company-Marches-Toward-UST-Commercial-Release-Up-listing-and-Profitability
$PBIO Replay Emerging Growth 12/ IHub Conference:
Youtube Link and Next Conference Link Here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165086789
$PBIO
$CLNV
$CLIS
$BETRF
$BMIX
$DMAN
$PIXY
$TCFF
$YEG
$WNRS
$GROM
Who do you want to see on the next Conference?
Conference@EmergingGrowth.com
$PBIO Pressure BioSciences Announces Major Business Expansion, Establishing Eco-Friendly Agrochemicals Subsidiary and Initiating Plans to Drive Accretive 2021 Revenue https://www.stocktitan.net/news/PBIO/pressure-bio-sciences-announces-major-business-expansion-nx6016b6d29u.html
$PBIO CEO Live on the Emerging Growth / Investors Hub Conference in 30 minutes
Registration Link:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165022424
Other Companies Presenting:
$PBIO
$CLNV
$CLIS
$BETRF
$BMIX
$DMAN
$PIXY
$TCFF
$YEG
$WNRS
$GROM
$PBIO Live Today on the Emerging Growth 12 / Investors Hub Virtual Investor Conference
9:00 AM Eastern Time
Registration Link Here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165021499
All of the Companies Presenting:
$PBIO
$CLNV
$CLIS
$BETRF
$BMIX
$DMAN
$PIXY
$TCFF
$YEG
$WNRS
$GROM
$PBIO Pressure BioSciences to Expand on Recent UST Platform Breakthroughs and Impending Agrochem Asset Acquisition at Upcoming Emerging Growth Conference https://www.accesswire.com/656274/Pressure-BioSciences-to-Expand-on-Recent-UST-Platform-Breakthroughs-and-Impending-Agrochem-Asset-Acquisition-at-Upcoming-Emerging-Growth-Conference
$PBIO Presenting Live on the Emerging Growth 12 / Investors Hub Conference this Wednesday July 21, 2021.
Registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164994160
$PBIO Exclusive Interview | Power Hour | Stock Market Live
$PBIO Pressure BioSciences UST-Enabled Nanoemulsions Soar Past One Year Stability Goal; Results Open Explosive Growth Potential for Water-Soluble CBD-Infused Beverages Worldwide https://www.accesswire.com/655299/pressure-biosciences-ust-enabled-nanoemulsions-soar-past-one-year-stability-goal-results-open-explosive-growth-potential-for-water-soluble-cbd-infused-beverages-worldwide
New group of investors led by Ming the Merciless powers PBIO up to $4.69
$PBIO Hit $3.80 Today see Article
An Antioxidant 6,000x Stronger Than Vitamin C Will Soon Be Available in Infused Beverage and Topical Treatment Form
https://www.benzinga.com/general/biotech/21/07/21854269/an-antioxidant-6-000x-stronger-than-vitamin-c-will-soon-be-available-in-infused-beverage-and-topi
$PBIO - Emerging Growth / Investors Hub Conference Replay available here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164694718
$PBIO Conference Replay now available.
Conference Replay and next conference registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164585602
$PBIO Live on the The Emerging Growth / Investors Hub Conference in 30 minutes!
Registration link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164551766
Other Companies Presenting Today:
$CLXPF
$RKV
Follow for Replay Notification
$NSAV & VirtuaBroker
$LQAVF / $LQID
$ERVFF / $EV
$FTXP
$GSVRF / $GSVR
$PHIL
$CBDD
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
28492
|
Created
|
12/19/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |